Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma

Journal of Proteome Research

Volumn 13, Issue 5, 2014, Pages 2250-2261

  Kubota, Daisuke ^a,b   Yoshida, Akihiko ^b   Kawai, Akira ^b   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

2D DIGE; alveolar soft part sarcoma; PP2A; SET

Indexed keywords

ANTINEOPLASTIC AGENT; FYN 720; FYN720; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN; SET PROTEIN; UNCLASSIFIED DRUG; CHAPERONE; ENZYME ACTIVATOR; FINGOLIMOD; PHOSPHOPROTEIN PHOSPHATASE 2; PROPANEDIOL DERIVATIVE; PROTEOME; SET PROTEIN, HUMAN; SPHINGOSINE; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ADOLESCENT; ADULT; ALVEOLAR SOFT PART SARCOMA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GEL ELECTROPHORESIS; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; CELL MOTION; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; PROCEDURES; RNA INTERFERENCE; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; YOUNG ADULT;

ADOLESCENT; ADULT; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME ACTIVATORS; FEMALE; HISTONE CHAPERONES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROPYLENE GLYCOLS; PROTEIN PHOSPHATASE 2; PROTEOME; PROTEOMICS; RNA INTERFERENCE; SARCOMA, ALVEOLAR SOFT PART; SPHINGOSINE; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84899833806     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr400929h     Document Type: Article

References (37)

1. Christopherson, W. M.; Foote, F. W., Jr.; Stewart, F. W. Alveolar soft-part sarcomas; structurally characteristic tumors of uncertain histogenesis Cancer 1952, 5 (1) 100-111
2. Ladanyi, M.; Lui, M. Y.; Antonescu, C. R.; Krause-Boehm, A.; Meindl, A.; Argani, P.; Healey, J. H.; Ueda, T.; Yoshikawa, H.; Meloni-Ehrig, A.; Sorensen, P. H.; Mertens, F.; Mandahl, N.; van den Berghe, H.; Sciot, R.; Dal Cin, P.; Bridge, J. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 Oncogene 2001, 20 (1) 48-57
3. Lazar, A. J.; Das, P.; Tuvin, D.; Korchin, B.; Zhu, Q.; Jin, Z.; Warneke, C. L.; Zhang, P. S.; Hernandez, V.; Lopez-Terrada, D.; Pisters, P. W.; Pollock, R. E.; Lev, D. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma Clin. Cancer Res. 2007, 13 (24) 7314-7321
4. Stockwin, L. H.; Vistica, D. T.; Kenney, S.; Schrump, D. S.; Butcher, D. O.; Raffeld, M.; Shoemaker, R. H. Gene expression profiling of alveolar soft-part sarcoma (ASPS) BMC Cancer 2009, 9, 22
5. Covell, D. G.; Wallqvist, A.; Kenney, S.; Vistica, D. T. Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets PLoS One 2012, 7 (11) e48023
6. Bisogno, G.; Rosolen, A.; Carli, M. Interferon alpha for alveolar soft part sarcoma Pediatr. Blood Cancer 2005, 44 (7) 687-688
7. Roozendaal, K. J.; de Valk, B.; ten Velden, J. J.; van der Woude, H. J.; Kroon, B. B. Alveolar soft-part sarcoma responding to interferon alpha-2b Br. J. Cancer 2003, 89 (2) 243-245
8. Kuriyama, K.; Todo, S.; Hibi, S.; Morimoto, A.; Imashuku, S. Alveolar soft part sarcoma with lung metastases. Response to interferon alpha-2a? Med. Pediatr. Oncol. 2001, 37 (5) 482-483
9. Azizi, A. A.; Haberler, C.; Czech, T.; Gupper, A.; Prayer, D.; Breitschopf, H.; Acker, T.; Slavc, I. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma Lancet Oncol. 2006, 7 (6) 521-523
10. Mir, O.; Boudou-Rouquette, P.; Larousserie, F.; Blanchet, B.; Babinet, A.; Anract, P.; Goldwasser, F. Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma Anticancer Drugs 2012, 23 (7) 745-748
11. Demetri, G. D.; van Oosterom, A. T.; Garrett, C. R.; Blackstein, M. E.; Shah, M. H.; Verweij, J.; McArthur, G.; Judson, I. R.; Heinrich, M. C.; Morgan, J. A.; Desai, J.; Fletcher, C. D.; George, S.; Bello, C. L.; Huang, X.; Baum, C. M.; Casali, P. G. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 2006, 368 (9544) 1329-1338
12. Stacchiotti, S.; Tamborini, E.; Marrari, A.; Brich, S.; Rota, S. A.; Orsenigo, M.; Crippa, F.; Morosi, C.; Gronchi, A.; Pierotti, M. A.; Casali, P. G.; Pilotti, S. Response to sunitinib malate in advanced alveolar soft part sarcoma Clin. Cancer Res. 2009, 15 (3) 1096-1104
13. Stacchiotti, S.; Negri, T.; Zaffaroni, N.; Palassini, E.; Morosi, C.; Brich, S.; Conca, E.; Bozzi, F.; Cassinelli, G.; Gronchi, A.; Casali, P. G.; Pilotti, S. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect Ann. Oncol. 2011, 22 (7) 1682-1690
14. Hanash, S. Progress in mining the human proteome for disease applications OMICS 2011, 15 (3) 133-139
15. Balgley, B. M.; Guo, T.; Zhao, K.; Fang, X.; Tavassoli, F. A.; Lee, C. S. Evaluation of archival time on shotgun proteomics of formalin-fixed and paraffin-embedded tissues J. Proteome Res. 2009, 8 (2) 917-925
16. von Lindern, M.; van Baal, S.; Wiegant, J.; Raap, A.; Hagemeijer, A.; Grosveld, G. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene Mol. Cell. Biol. 1992, 12 (8) 3346-3355
17. Li, M.; Makkinje, A.; Damuni, Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A J. Biol. Chem. 1996, 271 (19) 11059-11062
18. Seshacharyulu, P.; Pandey, P.; Datta, K.; Batra, S. K. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer Cancer Lett. 2013, 335 (1) 9-18
19. Kondo, T.; Hirohashi, S. Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics Nat. Protoc. 2006, 1 (6) 2940-2956
20. Perrotti, D.; Neviani, P. Protein phosphatase 2A: a target for anticancer therapy Lancet Oncol. 2013, 14 (6) e229-e238
21. Perrotti, D.; Neviani, P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias Cancer Metastasis Rev. 2008, 27 (2) 159-168
22. Yasui, H.; Hideshima, T.; Raje, N.; Roccaro, A. M.; Shiraishi, N.; Kumar, S.; Hamasaki, M.; Ishitsuka, K.; Tai, Y. T.; Podar, K.; Catley, L.; Mitsiades, C. S.; Richardson, P. G.; Albert, R.; Brinkmann, V.; Chauhan, D.; Anderson, K. C. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance Cancer Res. 2005, 65 (16) 7478-7484
23. Nagahara, Y.; Ikekita, M.; Shinomiya, T. T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2 Br. J. Pharmacol. 2002, 137 (7) 953-962
24. Matsumura, M.; Tsuchida, M.; Isoyama, N.; Takai, K.; Matsuyama, H. FTY720 mediates cytochrome c release from mitochondria during rat thymocyte apoptosis Transpl. Immunol. 2010, 23 (4) 174-179
25. Kayton, M. L.; Meyers, P.; Wexler, L. H.; Gerald, W. L.; LaQuaglia, M. P. Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults J. Pediatr. Surg. 2006, 41 (1) 187-193
26. Soft Tissue Tumor Registry in Japan, 2010.
27. Kondo, T.; Hirohashi, S. Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics Nat. Protoc. 2007, 1 (6) 2940-2956
28. Cervoni, N.; Detich, N.; Seo, S. B.; Chakravarti, D.; Szyf, M. The oncoprotein Set/TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing J. Biol. Chem. 2002, 277 (28) 25026-25031
29. Piazza, R.; Valletta, S.; Winkelmann, N.; Redaelli, S.; Spinelli, R.; Pirola, A.; Antolini, L.; Mologni, L.; Donadoni, C.; Papaemmanuil, E.; Schnittger, S.; Kim, D. W.; Boultwood, J.; Rossi, F.; Gaipa, G.; De Martini, G. P.; di Celle, P. F.; Jang, H. G.; Fantin, V.; Bignell, G. R.; Magistroni, V.; Haferlach, T.; Pogliani, E. M.; Campbell, P. J.; Chase, A. J.; Tapper, W. J.; Cross, N. C.; Gambacorti-Passerini, C. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia Nat. Genet. 2013, 45 (1) 18-24
30. Ivaska, J.; Nissinen, L.; Immonen, N.; Eriksson, J. E.; Kahari, V. M.; Heino, J. Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta Mol. Cell. Biol. 2002, 22 (5) 1352-1359
31. Janssens, V.; Goris, J.; Van Hoof, C. PP2A: the expected tumor suppressor Curr. Opin. Genet. Dev. 2005, 15 (1) 34-41
32. Switzer, C. H.; Cheng, R. Y.; Vitek, T. M.; Christensen, D. J.; Wink, D. A.; Vitek, M. P. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy Oncogene 2011, 30 (22) 2504-2513
33. Feschenko, M. S.; Stevenson, E.; Nairn, A. C.; Sweadner, K. J. A novel cAMP-stimulated pathway in protein phosphatase 2A activation J Pharmacol. Exp. Ther. 2002, 302 (1) 111-118
34. Neviani, P.; Santhanam, R.; Trotta, R.; Notari, M.; Blaser, B. W.; Liu, S.; Mao, H.; Chang, J. S.; Galietta, A.; Uttam, A.; Roy, D. C.; Valtieri, M.; Bruner-Klisovic, R.; Caligiuri, M. A.; Bloomfield, C. D.; Marcucci, G.; Perrotti, D. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein Cancer Cell 2005, 8 (5) 355-368
35. Matsuoka, Y.; Nagahara, Y.; Ikekita, M.; Shinomiya, T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells Br. J. Pharmacol. 2003, 138 (7) 1303-1312
36. Perrotti, D.; Neviani, P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia Br. J. Cancer 2006, 95 (7) 775-781
37. George, S.; Merriam, P.; Maki, R. G.; Van den Abbeele, A. D.; Yap, J. T.; Akhurst, T.; Harmon, D. C.; Bhuchar, G.; O'Mara, M. M.; D'Adamo, D. R.; Morgan, J.; Schwartz, G. K.; Wagner, A. J.; Butrynski, J. E.; Demetri, G. D.; Keohan, M. L. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas J. Clin. Oncol 2009, 27 (19) 3154-3160